Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer

NCT07745361 is registered in ClinicalTrials.gov with Monte Rosa Therapeutics, Inc as lead sponsor.

NCT NCT07745361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07745361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer
Lead sponsor
Monte Rosa Therapeutics, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
August 18, 2026
Completion date
April 30, 2028
Enrollment
25 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, castration-resistant prostate cancer (crpc), prostate cancer, prostate cancer (adenocarcinoma)